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An audit has been carried out into UK glomerular filtration rate (GFR) 
calculation. The results were compared to an identical 2001 audit. 
 
Method:  
Participants used their routine method to calculate GFR for 20 data sets (4 
plasma samples) in millilitres/minute and also the GFR normalised for body 
surface area (BSA). Some unsound data sets were included in order to analyse 
the applied quality control (QC) methods. Variability between centres was 
assessed for each data set, compared with the national median and a reference 
value calculated using the method recommended in the BNMS guidelines. The 
influence of the number of samples on variability was studied. Supplementary 
data were requested on workload and methodology.  
 
Results:  
The fifty nine returns showed widespread standardisation. The applied early 
exponential clearance correction was the main contribution to observed 
variability. These corrections were applied by 97% of centres (50%-2001) with 
80% using the recommended averaged Brochner-Mortenson correction. 
Approximately 75% apply the recommended Haycock BSA formula for adults 
(78% paediatric). The effect of the number of samples used was not significant. 
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There was a wide variability in the applied QC techniques, especially in terms of 
the use of the volume of distribution.  
 
Conclusion:  
The widespread adoption of the guidelines has harmonised national GFR 
calculation compared with the previous audit. Further standardisation could 
further reduce variability. This audit has highlighted the need to address the 
national standardisation of QC methods. Radionuclide techniques are confirmed 
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A previous national audit in 2001 showed significant variability in the methods 
used for calculating glomerular filtration rate (GFR), with some considerable 
outliers [1]. This led to the publication of guidelines by the British Nuclear 
Medicine Society (BNMS) on GFR measurement with plasma sampling in 2004 
[2]. The guidelines presented a standardised method of processing and 
analysing GFR studies in order to avoid variation in national GFR 
measurement. The International Scientific Committee of Radionuclides in 
Nephrourology (ISCORN) has recommended guidelines for GFR measurement 
in adults and children [3]. The European Association of Nuclear Medicine 
(EANM) has recommended paediatric guidelines [4]. The Nuclear Medicine 
Software Quality Group (NMSQG) of the Institute for Physics and Engineering 
in Medicine (IPEM) now present a repeat GFR audit in order to investigate 
whether the BNMS guidelines have been adopted in the UK. 
 
Radionuclide-based GFR measurement is used clinically as a reliable and 
accurate measure of kidney function. A technical review of GFR studies can be 
found elsewhere [5]. This technique is commonly used in the evaluation and 
monitoring of renal function in cases of chronic kidney disease, throughout 
courses of nephrotoxic drugs [6,7] and for the evaluation of renal function in 
potential live donors amongst other applications [2]. Radionuclide-based 
techniques allow for the measurement of GFR from plasma samples taken after 
the intravenous administration of a radionuclide-labelled tracer bolus (Cr51-
ethylenediaminetetraacetic acid (EDTA) or Tc99m diethylene-triamine-
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pentaacetic acid (DTPA) are used in the UK). The tracer diffuses between 
intravascular and extravascular spaces and mixes throughout the extracellular 
fluid volume (ECFV); both spaces can be considered to be tracer 
compartments. The tracer is only cleared by glomerular filtration. GFR can be 
measured and calculated through the quantification of plasma and standard-
volume sample(s) activity using a gamma-counter. It is known that patients with 
a fluid collection or various solid tumours can cause an inaccurate 
measurement due to the interference in tracer kinetics by this ‘third 
compartment’. This is a contraindication for GFR studies according to the 
BNMS guidelines [2]. 
 
The routine method of GFR measurement with a radionuclide involves 
measuring the area under the plasma clearance curve (AUC) [2,5]. GFR can be 
calculated by dividing the administered dose by the AUC. The AUC is 
characterised by the count rates from plasma samples obtained after 
administration of the tracer. The clearance curve is composed of two main 
exponential phases, early and late, but the late exponential dominates after 
approx 2 hrs [2,5]. Full characterisation of the clearance curve provides the 
most accurate and direct method of quantifying renal function [2,5,8,9]. 
However it requires an onerous number of plasma samples (>5 samples [5]), 
although the technique is described by the BNMS guidelines, full 
characterisation is not normally performed in routine practice. Instead a method 
involving two, three or four samples is recommended by the BNMS guidelines 
[2]. The guidelines do not recommend any single sample GFR methods. 




The BNMS recommend obtaining 2 to 4 venous blood samples between 2 and 
5 hours after tracer administration [2]. The samples are not started until two 
hours after administration to allow for complete mixing of the tracer throughout 
the ECFV. The whole-blood samples are centrifuged to isolate the plasma. The 
subsequently obtained plasma samples are part of the ‘late’ exponential phase 
of clearance. The count rates from these samples can be plotted against time. 
This allows for the definition of the ‘late’ exponential phase through the fitting of 
an exponential. A linear fit can also be performed if the natural logarithm of the 
samples counts is used. The AUC of the fitted exponential can be calculated by 
extrapolation. This method of AUC calculation (and hence GFR calculation) is 
known as the slope-intercept (SI) method [5,2] and was investigated in the last 
audit [1]. The SI method allows for the calculation of the tracer volume of 
distribution in the patient, this can be considered to be the ECFV. 
 
The SI method overestimates GFR by ignoring the AUC contribution from the 
early exponential phase [5,2]. This overestimated GFR is known as the 
uncorrected GFR (ml/min). It has been shown that this overestimation is 
systematic and increases with increasing GFR [1]. The BNMS recommend a 
quadratic correction for the early phase contribution called the averaged 
Brochner-Mortensen (ABM) correction to overcome this overestimation [2]. The 
volume of dilution can also be corrected in this way and it can be used for 
quality control (QC) purposes [2]. The ABM correction is applied to the body 
surface area (BSA) normalised uncorrected GFR measurement 
UK GFR audit 2013 Page 8 of 40 
GFR_audit_2013_v10 
 
(ml/min/1.73m2). The ECFV has also been suggested as a means of 
normalising GFR [10]. The BNMS recommend the Haycock BSA formula [11] 
for adults and paediatrics. The magnitude of the applied ABM correction is 
dependent on the GFR and the BSA of the patient [1]. The BNMS recommend 
that this normalisation is reversed, after AUC correction, to calculate the 
absolute (corrected) GFR [2]. The absolute GFR cannot be directly calculated 
using the SI method. 
 
The overall aim of the audit was to perform a repeat national investigation into 
the consistency of both the method and results of SI GFR measurement using 
plasma sampling. The first objective was to determine the variability between 
the participating centres for GFR measurement. The second objective was to 
investigate the adoption of current BNMS GFR guidelines and the third 
objective was to investigate the variability of QC techniques. 
 
Method 
Audit Methodology  
Twenty data sets were distributed nationally via regional coordinators and a UK 
medical physics electronic mail base. The first 10 data sets were the same as 
those used in the previous audit and these were included to allow for a direct 
comparison with the previous results. Each data set comprised count rate 
measurements from four plasma samples taken at specified times after the 
injection of Cr51-EDTA. The administered activities were in line with national 
guidance [12] (max administered activity of 3 MBq). A standard sample count 
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rate measurement and the details of the patient demographics (age/sex/height 
and weight) were also included (See Table 1). All data sets had standard 
dilution volumes of 250 ml but instructions were provided to explain how to alter 
the counts per minute for the standard sample in cases of software with hard 
coded standard volumes other than 250 ml.  
 
Participating centres were asked to apply their routine method to calculate the 
GFR for each data set, expressing the results as BSA normalised and non-
normalised GFR. Participants were asked to use the sample data closest to 
their routine blood sample timing schedule. Supplementary data were requested 
on workload, normal practice and the applied methodologies.  
 
A total of 64 returns were received from 59 centres (2001: 79 returns from 72 
centres). One centre submitted two returns (single-sample and 3-sample 
method) and one centre submitted three returns (2, 3 and 4-sample method). 
One centre submitted a return for their current method and also a proposed new 
method. Only the returns following their routine SI method (59 in total) were 
analysed. The results were processed and returned, via email, within a period of 
7 months. Results for the additional returns were also returned to the respective 
centres. Graphs were provided (in ml/min and ml/min/1.73m2) presenting the 
plots of the submitted results against the national median results and the results 
of a reference method. The reference result for each data set was calculated by 
the NMSQG following the BNMS guidelines. Participants with outlying results 
were offered support and guidance. Centres were asked to resubmit 
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recalculations for any data set returns that were suspected to contain errors. 
These returns were identified by deviation from the observed systematic trends. 
Participants also received a report summarising workload, normal practice and 
applied methodologies on a national level.  
Statistical analysis 
Descriptive statistics were calculated for the GFR values returned for each data 
set (in ml/min and ml/min/1.73m2). The quartile values and interquartile ranges 
were studied for the returns of each data set as they were not normally 
distributed. Pearson correlations were computed to assess the relationship 
between the national median results for each data set and the reference results 
using SPSS version 19 (SPSS IBM, New York, U.S.A). 
 
The absolute and BSA normalised GFR returns were divided into three groups 
according to whether two, three or four samples were used. The median values 
for each data set in each group were calculated. These median values were 
considered to be less affected by outliers than the average value. These values, 
for both the absolute and BSA normalised GFR returns, were used to assess 
the significance of the influence of the number of samples on the audit returns 
using the Kruskal–Wallis test (alpha = 0.05) using SPSS. The last audit only 
applied the Kruskal–Wallis test to the BSA normalised GFR returns. 
 
Error analysis 
The error analysis from the previous audit [1] was repeated. The results from 
the previous audit were compared with the results for the first ten data sets in 
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this audit because these were identical. The results in the previous audit were 
tabulated in the form of vijk where ‘i’ is the centre number using an analysis 
technique, ‘j’ is the applied analysis technique and the data set number is 
denoted by ‘k’. 
 
The variation (standard deviation) of the results was expressed in two ways in 
both ml/min and ml/min/1.73m2. Firstly the variation is presented relative to the 
overall mean of results for a particular data set. It provides a measure of the 
broad variation between all participants ignoring the applied analysis 
techniques. The variation is due to both the application of different analysis 
techniques and the differences in the execution of each technique. 
 
The second method of expressing variation was calculated only for centres 
following the BNMS guidelines (ABM correction and Haycock BSA formula in 
the correct order). This variation removes systematic differences between the 
analysis techniques and allows the random errors due to each participant’s 
implementation of the BNMS guidelines to be assessed independently. 
 
 
Errors related to overall means 
 
Errors were calculated in the same way as the last audit [1]. The overall mean 
result for all centres for a particular data set, k, is given by: 
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where m is the number of applied analysis techniques and nj is the number of 
participants using the analysis technique j.  
 
The standard deviation for all centres for a particular data set, k, compared with 
the overall mean for that data set is given by: 
 
 
The overall standard deviation or variation across all data sets is given by: 
 
where l is the number of data sets. 
 
Errors related to the inter-centre application of BNMS guidelines 
The standard deviation between all the centres applying the BNMS guidelines 
was calculated by following the same method as above but with the summation 
across the multiple techniques removed. 
 
Calculation of the RMedS and comparison to previous audit 
The previous audit [1] also calculated the variation in terms of the root median 
square (RMedS). The RMedS variation relative to the overall data set mean can 
be calculated in a manner analogous to the presented standard deviation above 
except that after calculating all the squared deviations from the mean the 
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median value of these squared deviations is used instead of the mean. RMedS 
has also been used in another previous audit [13]. For the purposes of allowing 
a direct comparison with the last audit the calculation of the RMedS was 
repeated. An advantage of the RMedS is that it is purposed to be more robust 
to outlying results and may therefore be a fairer representation of typical errors. 
The RMedS variation relative to the overall data set mean was recalculated and 
compared with the respective results from the previous audit. 
 
Quality control analysis 
Participants were asked to comment on the quality of sample count fits for each 
data set and note any actions undertaken during processing, as part of normal 
clinical practice. These responses were analysed.  
 
Eight of the data sets were technically unsound. Details can be found elsewhere 
(see pdf, Supplemental Digital Content 1, which contains further details). Some 
contained erroneous sample counts or timings and some had a volume of 
dilution above the expected range for adults defined in the guidelines which 
could be an indication of extravasation of the administered tracer or failure to 
inject all the calibrated activity. These issues were expected to be detected 
during processing and dealt with appropriately as per the BNMS guidelines. As 
the participants applied their routine processing method, these responses were 
used to study the national variation in QC. Data sets 1, 5, 7 and 9 were included 
in the first audit (before the guidelines were adopted) and they have been 
retrospectively considered unsound based on the current BNMS guidelines. 
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Data sets 12, 16, 17 and 18 were deliberately constructed as unsound for the 





The results are presented in two parts. The analysis of the submitted 
supplementary audit data (workload, normal practice and applied 
methodologies) is presented first. The results from the last audit, where 
available, are presented in brackets. The analysis of the returned measured 
GFR values from the audit data sets are presented second. All GFR results 
were rounded to nearest whole number. 
 
Supplementary audit data 
A total of 59 centres (2001: 72 centres) replied to the audit. Thirty five centres 
said they participated in the last audit, 10 said they did not, 3 centres provided 
no response and 11 did not know (mostly due to staff changes). When asked if 
they had changed their calculation method since the last audit, 38 centres said 
yes, 6 said no, 5 did not know, 8 provided no response and 2 stated that their 
GFR service started after the last audit. 
 
The median annual number of studies per centre is 200 with a maximum of 
2000 and a minimum of 2 studies. (2001: median 150, max 2300). Figure 1 is a 
histogram of the annual number of studies per centre. There were a total of 
UK GFR audit 2013 Page 15 of 40 
GFR_audit_2013_v10 
 
approximately 16,800 GFR studies performed each year in the UK by the 
participating centres. According to the returns, there has been a reduction in the 
number of centres currently offering GFR studies, but on average these 
individual centres appear to be performing more studies per year compared to 
the last audit. The reasons for renal function assessment referrals were as 
follows: 70% - oncology patients, 16% - Renal function assessment in living 
donors, 10% renal patients, 1% - dermatology and 3% - others (2001: 75% 
oncology, 19% renal, and 6% others). 
 
Fifty seven centres provided information on the type of radionuclide tracer being 
used. Forty five (79%) centres use Cr51-EDTA and twelve (21%) centres use 
99mTc-DTPA. This is identical to the last audit.  
 
The percentages of participants using each number of plasma samples was as 
follows: 2 samples – 49% (2001: 44%), 3 samples – 31% (2001: 32%) and 4 
samples – 20% (2001: 18%). One centre (1.7%, 2001: 6%) routinely use a 
single sample method (Watson [14] modified Christensen and Groth [15] 
method) for GFR assessment.  
 
Participants were asked what AUC correction, if any, was used. Fifty eight 
centres (98%) (2001: 50%) were using a correction of some sort. This 
compared to approximately 40-45% of participants in the last audit who were 
not using an AUC correction with the SI method. Two centres used both the 
adult [16] and child [17] Brochner-Mortensen correction in clinical practise 
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where appropriate. For those participants applying a correction, the most 
popular were the ABM [2] (80%) and the Brochner-Mortenson correction for 
adults [16] (11%). Two centres were using the Chantler correction [2] which 
involves AUC correction though multiplication with a constant factor. Further 
details are provided in Table 2. Ten centres were found to be performing the 
AUC correction and body size normalisation in the wrong order. There were 
nineteen centres (32%) in total that were applying specifically the ABM 
correction and Haycock BSA formula in the right order as per the BNMS 
guidelines. 
 
Fifty nine centres replied to the question about body size normalization. All 
participants normalised to BSA. Two centres had previously normalised to 
ECFV in the last audit. Seventy-five percent and seventy-eight percent of 
responding centres were using the BNMS recommended Haycock BSA formula 
for adults and paediatrics studies respectively. This is compared to seventy-five 
percent of centres using the Du Bois formula [18] in the last audit which did not 
differentiate between the usage on adults and paediatrics. A series of BSA 
formulae are being used in very small numbers [19-23]. Figure 2 provides a 
breakdown of the use of BSA formulae for adults and paediatrics. 
 
Participants were asked what actions would be undertaken for a GFR 
measurement study request in a patient with known fluid collection. This is a 
contraindication for a GFR study in the BNMS guidelines, as a fluid collection 
can affect the kinetics of plasma clearance from the intravascular volume, 
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invalidating the study. The breakdown of these responses by the percentage of 
participants for various actions is presented in table 3. Some centres provided 
more than one action. 
 
The replies of the participants were analysed in terms of the applied GFR 
normal ranges (if any). The ranges for both adults and paediatrics were both 
analysed. The breakdown of the percentage responses by centre number  
applying normal ranges in adults were as follows: Granerus and Aurell [24] – 29 
(49%); no response – 14 (24%); do not provide – 6 (10%); Grewal and Blake 
[25] – 5 (8%); use locally derived range – 3 (5%); values on EDTA 
manufacturers kit data sheet 1 (2%) and HJ Testa and MC Prescott [26] - 1 
(2%). The majority follow the normal range quoted by Granerus and Aurell [24] 
which is also suggested by the BNMS guidelines. The breakdown of the 
responses by centre number (%) applying normal ranges in paediatrics were as 
follows: no response – 15 (25%); do not perform paediatric studies – 14 (24%); 
do not provide – 13 (22%); Brochner-Mortensen corrected Piepsz-1994 method 
[27] – 6 (10%); Piepsz-1994 [28] – 5 (8%); use locally derived range – 3 (5%); 
Blake-2005 [29] – 2 (3%) and Piepsz-2006 [30] – 1 (2%).  
 
Statistical Analysis 
The results for the non-normalised and BSA normalised results are summarised 
in table 4 and 5 respectively. The returns for each data set were found to be not 
normally distributed or symmetrical in nature. The minimum, maximum, median, 
first and third quartile values were calculated to characterise the variability in 
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each data set. The standard deviation and RMedS were also calculated for 
each data set in order to allow for a direct comparison with the last audit. One 
centre provided no returns for data set 6 (data set with the smallest BSA) as 
they did not perform paediatric studies. Several participants provided non-
normalised returns only for other data sets for the same reason. 
 
The observed minimum and maximum interquartile ranges, in the non-
normalised results, were 0 and 16 ml/min respectively across all data sets. The 
maximum value was for patient 15. It had the third and fourth samples were 
swapped which led to the largest observed variation for all data sets. The 
average interquartile range was 2 ml/min across all data sets. This compared to 
an averaged full range of 25 ml/min across all data sets. The averaged full 
range for data sets 1 to 10 was 28 ml/min (2001: 42 ml/min). The drop in this 
averaged full range reflects an increase in precision.  
 
The first and third interquartile values were compared against the guidelines 
based results. The absolute average percent differences, for all data sets, were 
found to be less than 1.8% in both cases. The minimum and maximum full 
range values were also compared against the guidelines based result. The 
averaged minimum and maximum percent differences, for all data sets, were 
found to be -11 and 19% respectively. This suggests a greater tendency for the 
non-normalised GFR results to be overestimated (under AUC corrected) relative 
to the guidelines based result.  
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The variability of the BSA normalized results was very similar to that of non-
normalised results. This is to be expected as inconsistencies in the various 
applied BSA formulae would only contribute a relatively small amount of the 
observed variation. There was a respective minimum and maximum 
interquartile range of 0 and 12 ml/min/1.73m2 across the body-size normalised 
data sets. The maximum value was again observed for patient 15. There was 
an average interquartile range of 2 ml/min/1.73m2 in contrast to an averaged full 
range of 28 ml/min/1.73m2 across all data sets. The averaged full range across 
data set 1-10 in was 33 ml/min/1.73m2 (2001: 41 ml/min/1.73m2). The drop in 
the averaged full range since the last audit indicates an improvement in 
precision.  
 
The first and third interquartile values, for the BSA normalized results, were also 
compared with the reference results calculated following the BNMS guidelines. 
The absolute average percent differences, for all data sets, in both situations 
were less than 2.2%. The minimum and maximum full range values were 
compared with the reference result. The averaged minimum and maximum 
percent differences, for all data sets, were found to be -13% and 23% 
respectively. This again indicates a tendency to overestimate the GFR result. 
 
Interquartile ranges were not available for the 2001 audit but the averaged full 
range for data sets 1 to 10 was seen to decrease (in both ml/min and 
ml/min/1.73m2) indicating better accuracy, most likely due to standardisation. 
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Significant correlations (Pearson r = 1.0, 2-tailed, p < .001) were found between 
the median results for each data set (in both ml/min and ml/min/1.73m2) and the 
reference results calculated following the BNMS guidelines.  
 
The Kruskal–Wallis test found that the difference between the median values, 
for each data set, of the grouped returns (2, 3 or 4 plasma samples) was not 
significant at the 0.05 level. The last audit found that this result was ‘just 
significant’ for the BSA normalised GFR data. This change in significance is 
mostly likely due to the standardisation of the GFR study processing since the 
last audit. 
 
Error analysis compared to overall mean 
The overall standard deviation in the non-normalized results for the first ten data 
sets was 4.8 (2001: 10.1) ml/min, whereas the corresponding RMedS variation 
was 1.3 (2001: 5.8) ml/min. There is a noticeable reduction in these values 
since the last audit. It is probably because there were fewer outliers in this audit 
and this may explain the similarity of both the standard deviation and RMedS 
results. This may be attributable to the considerable national adoption of the 
BNMS guidelines since the last audit. The overall standard deviation and 
RMedS variation for all twenty data sets were 4.8 and 2.6 ml/min respectively.  
 
Similar values were calculated for the BSA normalised returns. The overall 
standard deviation for the first ten data sets in this audit was 5.9 (2001: 10.3) 
ml/min/1.73 m2, whereas the corresponding RMedS variation was 1.84 (2001: 
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5.8) ml/min/1.73 m2. The overall standard deviation and RMedS variation for all 
twenty data sets were 5.2 and 2.4 ml/min/1.73m2 respectively. 
 
Errors related to the inter-centre application of BNMS guidelines 
The variability of the results was analysed for the 19 centres fully adopting the 
ABM correction and Haycock BSA formula. There was little variability for both 
ml/min and ml/min/1.73m2. For the non-normalised results, the averaged 
standard deviation and RMedS variation were less than 2.4 ml/min for all twenty 
data sets (< 0.6 ml/min for data sets 1 to 10). While for the BSA normalised 
results the standard deviation and RMedS variation were less than 2.1 
ml/min/1.73m^2 for all twenty data sets (< 0.7 ml/min/1.73m^2 for data sets 1 to 
10). The difference in the results for all data sets and just the first ten may be 
largely due to inclusion of data set 15 (large variation in the returns). 
 
These results confirm that the adoption of the ABM correction has led to a more 
precise technique for the non-normalised measurement of GFR. The remaining 
variability may be due to rounding errors and other minor contributions such as 
the varying least square fitting methods employed by each centre.  
 
 
Quality control analysis 
The analysis of the QC responses, for all data sets, submitted by participants is 
shown in Figure 3. The percentages of responses for various QC issues were 
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aggregated to simplify presentation. The responses relating to the unsound data 
sets show a poor detection rate.  
 
The results for data sets with high calculated volume of dilution (data sets 1, 7, 
9 and 18) show that this issue was detected, in the worst case (data set 7), by a 
minimum of 42% of participants. It would appear that the majority of centres do 
not study the volume of dilution as a QC technique or at least in a consistent 
way. Upon analysis of the returns, it was found that 78% of centres were not 
correcting the volume of dilution, 12% provided no volume of dilution data, 7% 
are correcting the volume of dilution and 3% appear to be incorrectly correcting 
the volume of dilution (although their returns contained GFR results in line with 
the BNMS guidelines based results). It should be noted that one centre was not 
applying an AUC correction so they could not correct the volume of dilution. 
 
Unfortunately the correction of the volume of dilution is not directly mentioned in 
the guidelines. The effect of not applying the correction produces an artificially 
high volume of dilution. In this case, normal ranges defined in the BNMS 
guidelines may lead to some studies being incorrectly reported as 'potentially 
inaccurate' due to the incorrectly high volume of dilution. This may be leading to 
unnecessary repeated studies. This may also help to explain the relatively small 
yet consistent number of ‘high volume of dilution ' QC responses for the sound 
data sets in figure 3. 
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The results for the data sets with sample count or timing anomalies (data sets 5, 
12 15 and 17) show that these issues were detected, in the worst case by a 
minimum of 22% of participants. This was in the case of data set 12 that had an 
early first sample (only 62 minutes post administration). Only seven centres 
(12%) questioned if the samples for data set 15 were swapped as they had 
been. The distribution of the absolute GFR results for data set 15 is presented 
in figure 4. This shows that there may not be a consistent method of analysing 
the goodness of fit to the count data in GFR studies. There is a troublingly large 
spread (46-74 ml/min) in the returned absolute GFR results for data set 15. The 
guidelines suggest that if 3 or 4 samples are used then the goodness of fit to a 
single exponential should be checked by a visual method or by the value of the 
correlation coefficient. The correlation coefficient r-value should be greater than 
0.985 for patients with a normal GFR. This should certainly have lead to 
rejection of the fit for data set 15, where the r-value was only 0.628, and also 
doubts about data sets 5 and 17. Anomalies may have been missed by some 
centres using only 2 or 3 samples if certain samples were ignored because they 
did not match a specific local sampling schedule. However, it was hoped that in 
the spirit of the audit these anomalies would have been detected and at least 
commented upon by participants.  
 
In general more centres detected issues in the sample count or timing 
anomalies than with the volume of dilution, but a worryingly large percentage of 
centres failed to query the quality of the unsound data sets. The results show 
that the QC of GFR measurement studies is not standardised. The QC 
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responses of seven centres (12%) mentioned the use of single sample GFR 
calculation as a means of QC for the slope-intercept studies. Although this 
useful QC method is not obligatory it could be implemented more frequently. 
 
Discussion 
The last audit demonstrated that there was significant national variation in GFR 
measurements. The results of this audit show that there has been an 
improvement in terms of accuracy and precision since the last audit through the 
widespread adoption of the BNMS guidelines. The consideration of the BNMS 
guidelines as a reference method allowed for the assessment of the accuracy of 
audit returns while the spread of the results for centres adopting the guidelines 
enabled precision to be investigated. The results of this audit reaffirm that 
radionuclide techniques are the preferred method for GFR measurement when 
an unequivocal result is required [31]. 
 
 
The vast majority of the participants (80%) are using the ABM correction during 
GFR measurements. This is in contrast to the last audit were only 51% of 
centres were performing a type of AUC correction. These results reflect the 
successful adoption of this aspect of the BNMS guidelines, although there is still 
scope for improvement. Non-standardised AUC correction is one of the greatest 
sources of variability especially as GFR increases. This audit showed that only 
2% of centres were not performing an AUC correction and 17% of participants 
were applying a non-recommended AUC correction. This audit presents an 
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opportunity for these centres to re-evaluate their practise in the context of 
national trends. This in itself represents one of the advantages of performing 
national audits; they allow outlying centres to confidentially improve their 
practice and avoid undue errors. It is appreciated that the adoption of a new 
AUC corrections in clinical practice is a challenging process and requires a lot 
of planning and a multi-disciplinary approach. 
 
There has been marked adoption of the recommended Haycock BSA formula. 
This standardisation is welcomed even though it is know that variability between 
the returns due to different BSA normalisation is relatively small compared to 
the variation from in the type of applied AUC correction. Although these minor 
systematic differences should be considered when interpreting results. The 
Haycock BSA formula is applied by 75% of participants for adult studies and 
78% of participants are applying it for paediatric studies. It may be 
advantageous to use a single BSA formula for both adult and paediatric studies. 
Relatively minor but undesirable systematic errors may occur over the transition 
between adult and paediatric formulae in a series of studies, in patients followed 
throughout adolescence to adulthood.  
 
The audit results found that ten centres were performing the AUC correction 
and body size normalisation in the wrong order. All of these centres were 
informed and given an explanation of why this was incorrect. This effect may 
lead to significant errors in paediatric studies. The theoretical results provided in 
the last audit found that the effect is small, in patients with GFR up to 
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approximately 80 ml/min/1.73m2. The result showed that the effect increases in 
significance as GFR increases above this level, particularly for participants with 
a BSA below 1m2. This poses obvious concerns for paediatric studies. In adults 
the effect is less of a concern and should not lead to a general systematic error, 
as on average the patients will have a BSA close to the standard of 1.73m2. It 
should be noted that this will have a detrimental effect on the precision of adult 
GFR studies. GFR is overestimated in adults with a relatively small BSA and 
vice versa. Fortunately this issue with the respective centres can now be 
remedied. 
 
The poor detection rate for the unsound data sets stresses the importance of 
the need for QC standardisation. The BNMS guidelines suggest that the results 
of each GFR calculation should be judiciously inspected to confirm the study 
results and count data is self-consistent before the clinical report is issued.  
  
The audit found that the majority of participants do not study the volume of 
dilution as a QC technique or at least not in a consistent way. The BNMS 
guidelines state that for adults the expected volume of dilution is around 8 times 
the BSA with a two standard deviation range of +/- 25% (that is it should be 
between 6 and 10 times BSA). This is translated in the guidelines to 11-17 litres 
in women and 13-20 litres in men. There can be a mixed interpretation of this 
with some centres taking these fixed figures as the expected range while some 
may calculate it for each patient based on the patient BSA. The expected range 
is also only defined for adults but some centres may apply it to paediatric 
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studies also by establishing the expected range on the BSA calculation. 
Hopefully the expected range can be described in a more specific way in the 
next version of the guidelines. Also it is hoped that an expected range for 
paediatrics will be described. 
 
Unfortunately the guidelines do not explicitly state that the expected range does 
not apply to the uncorrected volume of dilution (calculated from the intercept of 
the late phase exponential) but to the corrected volume of dilution. Since the 
uncorrected GFR is equal to the uncorrected volume of dilution multiplied by the 
exponential rate constant, by analogy the absolute GFR should be equal to the 
corrected volume of dilution multiplied by the same rate constant. The corrected 
GFR is derived by applying the ABM correction to the uncorrected GFR and so 
the corrected volume of dilution can be derived by applying the same ABM 
correction to the uncorrected volume of dilution.  Since the ABM correction 
factor is always less than 1.0, it follows that the corrected volume of dilution will 
always be less than the uncorrected volume of dilution. This was mentioned 
during a presentation [32] about the last audit results at a BNMS meeting but it 
was not directly mentioned in the published guidelines. The audit results 
demonstrate that the vast majority of centres (78%) in the UK are not correcting 
the volume of dilution calculated during GFR studies. A large percentage of 
centres may be applying the expected ranges from the guidelines to the 
uncorrected volume of dilution. Practically this may be leading to repeated 
studies in cases where an uncorrected volume of dilution is being used for QC. 
This oversight in the guidelines will hopefully be clarified in the next version of 
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the guidelines. Also a greater emphasis should be given to the study of the 
correlation value for fits to the plasma sample counts (r2>0.985) during QC. 
 
The audit found that the vast majority of participants were performing GFR 
studies in patients with known third compartments even though this is a 
contraindication in the BNMS guidelines. GFR studies within this sub-group are 
known to have a higher probability of causing inaccurate measurement due to 
the effect of the third compartments on tracer kinetics. This is of most concern 
in studies where the GFR measurement is used in chemotherapy dosing. This 
audit found that the main national use of GFR studies is for oncology purposes. 
The tumours being treated may be invalidating the very GFR study being used 
for chemotherapy dosing, leading to potential suboptimal chemotherapy 
treatments. The application of GFR studies on this sub-group and the related 
recommended contraindication should be readdressed in future guidelines.  
 
GFR measurement calculation is unique as there is no CE marked proprietary 
software available. Before the guidelines most centres used software that was 
developed in-house without guidance. This contributed to the significant 
variability in national GFR measurement as detected by the last audit. This led 
to the creation of the BNMS guidelines which recommended that a standard 
method of analysis to avoid undue variability. The repeat audit shows the wide 
spread adoption of these national guidelines on GFR. This repeat audit 
successfully completes the GFR measurement software audit loop and 
demonstrates core clinical governance values. This is a prime example of a 
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good audit process involving the commencement of an initial audit, analysing 
the results, identify issues, developing improvements / standards (in this case 
via national guidelines) and a follow-up audit. Feedback to the participants is 
paramount at each stage. While there is, as ever, the need for improvement this 
audit shows that the major issues with variability have been addressed on a 
national scale by the nuclear medicine community in the UK. This reduction in 
variability is advantageous considering the necessity of unequivocal nationally 
standardised GFR measurement.  
 
Another advantage of this audit is that it will allow for the benchmarking of GFR 
software against the current BNMS guidelines. The audit data sets, instructions 
and calculated results following the correct implementation the BNMS 
guidelines can be found on the NMSQG website (www.nmsqg.org). The 
lattermost of which can be found elsewhere (see pdf, Supplemental Digital 
Content 2, which contains the GFR calculation for each data set, following the 
current BNMS guidelines).  
 
Conclusion 
This audit has shown a significant reduction in the national variability of GFR 
measurement compared to the 2001 audit. The main source of the previous 
variability was due to different method of analysis chiefly varying AUC 
corrections. Ignoring outliers, the widespread adoption of the BNMS guidelines 
has relatively standardised national GFR measurement. More standardisation 
can further reduce the observed differences. This audit has highlighted the need 
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to address the standardisation of QC methods for GFR studies, particularly the 
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Figure 1  Histogram of the number of annual studies per UK centre 
Figure 2  Analysis of the national usage of BSA formulas. 
Figure 3  Analysis of the aggregated percentages of different types of QC 
responses, by participants for each data set. The data sets known to be 
technically unsound are highlighted with arrows. (VoD – Volume of dilution) 
 
Figure 4  Histogram of the responses (based on local protocol) for data set 15 
which had the 3rd and 4th samples swapped. The following are various 
calculated absolute GFR results for defined sample selections (following the 
BNMS guidelines) with the respective linear r2 values: (61 ml/min, all samples 
with 3rd and 4th samples swapped back, r2 = 0.995), (56 ml/min, all samples 
with 3rd and 4th samples not swapped, r2 = 0.628), (71 ml/min, (sample 1, 2 and 
3), r2 = 0.953), (46 ml/min, (sample 1, 2 and 4), r2 = 0.981). 
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Table 1     Data set for patient number 1 
Patient demographics 
Age (yrs) 54 
Sex M 
Height (m) 1.78 
Weight (kg) 70 
 
Data standard and doses 
Weight of syringe and patient dose (g) 6.573 
Weight of empty syringe (g) 4.535 
  
Weight of syringe and standard dose (g) 4.962 
Weight of empty syringe (g) 4.456 
  
Standard counts per minute 56450 
 
Plasma sample details 
















































UK GFR audit 2013 Page 37 of 40 
GFR_audit_2013_v10 
 
Table 2    Details of the AUC correction applied by the 59 participants. Two 
centres contributed both the adult and child correction. This produced a total of 
61 applied corrections. BM - Brochner-Mortenson, ABM - Averaged Brochner-
Mortenson, AUC- area under clearance curve 
 
Correction type                 Number (%) 
 
ABM   49  (80%) 
BM adult   7    (11%) 
 
BM child   2     (3%) 
 
Chantler   2     (3%) 
 
No correction                                   
     





Table 3    Actions for patients referred for GFR studies with known fluid 
collection. The percent of centres suggesting each individual action is 













37 Continue study with no more samples/ discard 1st sample  
31 Discuss with referrer/MPE/more experienced centre 
24 Make comment on report 
22 Continue study with more/ later samples 
14 Abandon study 
10 Delay study until fluid is drained 
10 Study  volume of dilution  and exponential fit 
2 Full characterisation with 7> samples 
2 Request patient to stop oedema medication 
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Table 4  Summary of non-normalised GFR results (millilitre/ minute) for the audit data sets 
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
 






























































146 80 110 25 58 48 80 75 112 94 





















180 101 128 29 74 52 92 84 131 107 
BNMS 134 80 51 84 112 71 34 26 117 141 147 80 110 25 61 47 79 75 112 93 
SD 8 (18) 2 (5) 2 (3) 2 (6) 4 (11) 6 (7) 2 (5) 1 (2) 6 (13) 8 (17) 7 5 4 1 10 1 3 1 4 3 
RMedS 2 (16) 1 (5) 0 (2) 1 (6) 1 (9) 3 (7) 0 (1) 0 (1) 2 (11) 1 (12) 1 2 1 0 10 0 1 1 1 1 
                     
 
 
Returns–number of returns, Min–minimum, Max-maximum, Qrt – quartile, SD –Standard deviation, RMedS - Root median square, The 
eight highlighted data set numbers represent the unsound data sets. The row marked ‘BNMS’ represents the reference value calculated 
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Table 5  Summary of BSA normalised GFR results (millilitre/ minute/1.73 m2) for the audit data sets 
 
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
                     
Returns 59 59 59 59 59 57 58 59 59 59 59 58 59 59 59 59 59 59 59 59 





















97 91 75 19 33 52 59 73 78 70 





















108 114 80 22 44 54 73 74 83 77 





















135 139 98 24 58 58 88 86 101 91 
BNMS 125 72 44 85 93 132 46 21 123 116 108 114 80 21 45 54 72 74 83 77 
SD 7 (18) 3 (5) 2 (3) 2 (6) 4 (9) 11 (14) 3 (5) 2 (2) 9 (14) 7 (15) 6 7 4 1 8 1 4 2 4 3 
RMedS 2 (16) 1 (5) 0 (2) 1 (6) 1 (7) 4 (14) 1 (2) 0 (1) 3 (13) 1 (10) 1 5 1 1 7 0 2 1 1 1 
 
 
Returns–number of returns, Min–minimum, Max-maximum, Qrt – quartile, SD –Standard deviation, RMedS - Root median square, BSA – 
Body surface area (m2) calculated from the patients height and weight with the Haycock formula. The eight highlighted data set numbers 
represent the unsound data sets. The row marked ‘BNMS’ represents the reference value calculated following the BNMS guidelines. 
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